Phase 2 Trial Shows Fibrosis Reduction in Some With Myelofibrosis
The phase 2a MYLOX-1 trial demonstrated fibrosis reduction in some patients with myelofibrosis who previously received treatment with Jakafi (ruxolitinib).
Source: curetoday.com
Hans Schambye News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Hans Schambye. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Hans Schambye Today - Breaking & Trending Today
Galecto Announces Plans to Explore Strategic Alternatives
BOSTON, Sept. 26, 2023 -- Galecto, Inc. , a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it has completed a...
Source: marketscreener.com
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
BOSTON, Aug. 15, 2023 -- Galecto, Inc. , a clinical-stage biotechnology company and world leader in galectin biology, focused on the development of novel treatments for fibrosis and cancer, today... -Today at 07:30 am- MarketScreener
Source: marketscreener.com
Galecto stock rises 12% as GB1211 shows efficacy in liver disease patients in trial
Galecto (GLTO) said its medicine GB1211 helped reduce certain liver enzymes in patients with decompensated cirrhosis in a phase 1b/2a trial.The study, dubbed GULLIVER-2, evaluated...
Source: seekingalpha.com
Galecto Reports First Quarter Operating and Financial
BOSTON, April 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel...
Source: globenewswire.com